|
🐢
|
Comprehensive analysis of the clinical immuno-oncology landscape
Jun Tang,
A. Shalabi,
Vanessa M Hubbard-Lucey
|
8 |
2018 |
8
🐢
|
|
🐜
|
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
145 auth.
Daniel K. Wells,
Marit M. van Buuren,
Kristen K. Dang,
Vanessa M Hubbard-Lucey,
K. Sheehan,
Katie M. Campbell,
Andrew Lamb,
J. Ward,
J. Sidney,
A. Blázquez,
A. Rech,
J. Zaretsky,
Begonya Comin-Anduix,
Alphonsus H. C. Ng,
W. Chour,
...
Thomas Yu,
H. Rizvi,
J. Chen,
Patrice A Manning,
Gabriela Steiner,
Xengie Doan,
T. Merghoub,
J. Guinney,
A. Kolom,
Cheryl Selinsky,
A. Ribas,
M. Hellmann,
N. Hacohen,
A. Sette,
J. Heath,
N. Bhardwaj,
F. Ramsdell,
R. Schreiber,
T. Schumacher,
P. Kvistborg,
N. Defranoux,
Aly A. Khan,
A. Lugade,
A. Lazic,
Angela Frentzen,
A. Tadmor,
A. Sasson,
A. Rao,
Baikang Pei,
Barbara Schrörs,
B. Berent-Maoz,
B. Carreno,
Bin Song,
Bjoern Peters,
B. Li,
B. Higgs,
Brian J. Stevenson,
C. Iseli,
Christopher A. Miller,
C. Morehouse,
C. Melief,
Cristina Puig-Saus,
Daphne van Beek,
D. Balli,
D. Gfeller,
D. Haussler,
D. Jäger,
E. Cortes,
Ekaterina Esaulova,
E. Sherafat,
Francisco Arcila,
G. Bartha,
Geng Liu,
G. Coukos,
Guilhem Richard,
Han Chang,
Han Si,
I. Zörnig,
I. Xenarios,
I. Măndoiu,
Irsan E. Kooi,
James P. Conway,
J. Kessler,
J. Greenbaum,
Jason F. Perera,
J. Harris,
J. Hundal,
Jennifer M. Shelton,
Jianmin Wang,
Jiaqian Wang,
J. Greshock,
Jonathon Blake,
J. Szustakowski,
Julia Kodysh,
J. Forman,
Lei Wei,
Leo J. Lee,
Lorenzo F. Fanchi,
M. Slagter,
Maren Lang,
Markus Mueller,
Martin Lower,
M. Vormehr,
M. Artyomov,
M. Kuziora,
M. Princiotta,
M. Bassani-Sternberg,
Mignonette H Macabali,
Milica R. Kojicic,
Naibo Yang,
N. Raicevic,
N. Guex,
N. Robine,
N. Halama,
Nikola Skundric,
Ognjen Milićević,
Pascal Gellert,
P. Jongeneel,
P. Charoentong,
P. Srivastava,
Prateek Tanden,
Priyanka Shah,
Q. Hu,
Ravi Gupta,
Richard O. Chen,
R. Petit,
R. Ziman,
R. Hilker,
S. Shukla,
Sahar Al Seesi,
S. Boyle,
S. Qiu,
Siranush Sarkizova,
S. Salama,
Song Liu,
Song Wu,
S. Sridhar,
S. Ketelaars,
S. Jhunjhunwala,
T. Shcheglova,
Thierry Schuepbach,
T. Creasy,
Veliborka Josipovic,
Vladimir B. Kovacevic,
W. Fu,
Willem-Jan Krebber,
Yi-Hsiang Hsu,
Y. Sebastian,
Zeynep Kosaloglu- Yalcin,
Zhiqin Huang
|
8 |
2020 |
8
🐜
|
|
🐬
|
Immunotherapy and targeted therapy combinations in metastatic breast cancer.
F. Esteva,
Vanessa M Hubbard-Lucey,
Jun Tang,
L. Pusztai
|
8 |
2019 |
8
🐬
|
|
🐬
|
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Jun Tang,
Jia Xin Yu,
Vanessa M Hubbard-Lucey,
Svetoslav T. Neftelinov,
J. Hodge,
Yunqing Lin
|
8 |
2018 |
8
🐬
|
|
🐜
|
Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium
18 auth.
Yu Matsuzawa-Ishimoto,
Y. Shono,
L. E. Gómez,
Vanessa M Hubbard-Lucey,
M. Cammer,
J. Neil,
M. Dewan,
Sophia R Lieberman,
A. Lazrak,
Jill M. Marinis,
...
A. Beal,
P. Harris,
J. Bertin,
Chen Liu,
Yi Ding,
M. Brink,
M. Brink,
K. Cadwell
|
7 |
2017 |
7
🐜
|
|
🐬
|
Immuno-oncology drug development goes global
Jia Xin Yu,
Vanessa M Hubbard-Lucey,
Jun Tang
|
7 |
2019 |
7
🐬
|
|
🐜
|
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
25 auth.
H. Kluger,
H. Tawbi,
M. Ascierto,
M. Bowden,
M. Callahan,
E. Cha,
Helen X. Chen,
C. Drake,
D. Feltquate,
R. Ferris,
J. Gulley,
Shilpa Gupta,
R. Humphrey,
T. Lavallee,
D. Le,
...
Vanessa M Hubbard-Lucey,
V. Papadimitrakopoulou,
M. Postow,
E. Rubin,
E. Sharon,
J. Taube,
S. Topalian,
R. Zappasodi,
M. Sznol,
R. Sullivan
|
7 |
2020 |
7
🐜
|
|
🐜
|
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
37 auth.
Lacey J Padrón,
Deena M. Maurer,
M. O'Hara,
E. O’Reilly,
R. Wolff,
Z. Wainberg,
A. Ko,
G. Fisher,
O. Rahma,
Jaclyn P. Lyman,
Christopher R Cabanski,
Jia Xin Yu,
Shannon M. Pfeiffer,
M. Spasić,
Jingying Xu,
...
P. Gherardini,
J. Karakunnel,
R. Mick,
Cécile Alanio,
Katelyn T Byrne,
T. Hollmann,
Jonni S. Moore,
Derek D Jones,
M. Tognetti,
Richard O Chen,
Xiaodong Yang,
Lisa Salvador,
E. Wherry,
U. Dugan,
Jill O'Donnell-Tormey,
L. Butterfield,
Vanessa M Hubbard-Lucey,
R. Ibrahim,
J. Fairchild,
Samantha Bucktrout,
T. Lavallee,
R. Vonderheide
|
7 |
2022 |
7
🐜
|
|
🐬
|
Trends in clinical development for PD-1/PD-L1 inhibitors
Jia Xin Yu,
J. Hodge,
C. Oliva,
Svetoslav T. Neftelinov,
Vanessa M Hubbard-Lucey,
Jun Tang
|
7 |
2019 |
7
🐬
|
|
🐜
|
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
32 auth.
M. O'Hara,
Eileen M. O’Reilly,
G. Varadhachary,
Robert A. Wolff,
Z. Wainberg,
Andrew H. Ko,
G. Fisher,
O. Rahma,
Jaclyn P. Lyman,
Christopher R Cabanski,
R. Mick,
P. Gherardini,
L. Kitch,
Jingying Xu,
T. Samuel,
...
J. Karakunnel,
J. Fairchild,
Samantha Bucktrout,
T. Lavallee,
Cheryl Selinsky,
Jacob E. Till,
Erica L Carpenter,
Cécile Alanio,
Katelyn T Byrne,
Richard O Chen,
O. Trifan,
U. Dugan,
C. Horak,
Vanessa M Hubbard-Lucey,
E. Wherry,
R. Ibrahim,
R. Vonderheide
|
7 |
2021 |
7
🐜
|
|
🐢
|
Trends in the global immuno-oncology landscape
Jun Tang,
L. Pearce,
Jill O'Donnell-Tormey,
Vanessa M Hubbard-Lucey
|
6 |
2018 |
6
🐢
|
